Order of the Presentation

• Access to Vivitrol (CABH & CARP)
• Screening, Assessment, Referral & Treatment
• Narcan Distribution
A. Access to Vivitrol
Treatment of OUD

- **Medication**
  - Control cravings (block negative reinforcement)
  - Prevent relapse (block positive reinforcement)

- **Community supports**
  - Peer support meetings
  - Sober social network
  - Family supports

- **Counseling**
  - Learn about addiction and recovery
  - Relapse prevention skills
  - Treatment of psychiatric co-morbidities
Vivitrol is an extended release injectable given once a month for Alcohol and Opioid dependence.

What are the Benefits of Vivitrol Treatment?

- Vivitrol is non-addictive
- It does not create a "high"
- Easier than daily oral medications
- Successful for both alcohol and opioids
- Effective for relapse prevention

CAHSD MAT Workgroup

• Executive Director
• Medical Director
• Director of Business Operations
• MH Clinical Services Director
• Staff Psychiatrist
• RN Supervisor
• Program Director for ARS
• Program Manager for ARS
• Consultants: Dr. Arwen Podesta and Gwendolyn Lastrapes
Workgroup Output

• Treatment model
  • Groups, individual therapy, peer support, MD visits, medication
• Screening
• Tx practices and protocols
• Physician protocols
• Consents
• Pregnancy Acknowledgement
• Clinic Procedure
Preparation

• Education & Training
  • MAT (Information and Stigma reduction)
  • Vivitrol (Alkermes)
    • Clinicians
    • Nurses
NOW ACCEPTING REFERRALS!

Center for Adult Behavioral Health
Scott Thomas, ARS Program Manager
225.362.5329 or Scott.Thomas@la.gov

Capital Area Recovery Program (CARP)
Dr. Joseph Pete, CARP Facility Manager
225.922.3177 or Joseph.Pete@la.gov
B. Screening, Assessment, Referral & Treatment
Screening, Assessment, Referral & Treatment

Pre-MAT Implementation

• All clients screened for problem substance use
• Assessed with Addiction Severity Index
• Referred to appropriate level of care (internal or external)
• Abstinence-based treatment services

Post-MAT Implementation

• All clients screened for problem substance use and interest in Vivitrol (if using opioids)
• Assessed with Addiction Severity Index
• Referred to appropriate level of care (internal or external) and peer support (STR)
• Abstinence-based treatment services and MAT (Vivitrol)
C. Narcan Distribution
WHAT IS NARCAN® NASAL SPRAY

NARCAN® (naloxone HCl) Nasal Spray is the first and only FDA-approved nasal form of naloxone for the emergency treatment of a known or suspected opioid overdose. NARCAN® Nasal Spray counteracts the life-threatening effects of opioid overdose. Since most accidental overdoses occur in a home setting, it was developed for first responders, as well as family, friends, and caregivers.
NARCAN (cont’d)

• Provided, by OBH, through STR funds
• CAHSD submitted a Narcan needs assessment
  • Surveyed treatment providers and community organizations
  • Determined target population and rationale
  • Developed dissemination and tracking plan
  • Received 1445 kits
• Over 500 kits disseminated
  • Working to create a model for access in EDs and for Community Paramedics who f/u after overdoses
  • Peers coordinating outreach to community organizations and CAHSD clients
  • Planning NARCAN training (coming soon: Date/time TBD)
Need Narcan for your organization? Contact CAHSD’s STR Peer Support Specialists

Tonja Myles
Tonja.Myles@la.gov

Ivan Toldson
Ivan.Toldson@la.gov
Questions?

Jan Laughinghouse

Janzlean.Laughinghouse@la.gov